Redx Pharma expects $125million Skye Bioscience deal to complete soon
Alderley Park based Redx Pharma made losses of £18.4 million (FY to 30 September 2024: £17.5 million) for the 15-month period ended 31 December 2025, following the change in the Company's financial year end from 30 September to 31 December.
However, Lisa Anson, Chief Executive Officer, Redx, said “significant progress” in clinical development capabilities puts the business on a strong footing and expects its deals with Skye Bioscience to complete this year and deliver aggregate gross proceeds of up to $125 million.
“We e... You can carry on reading TheBusinessDesk.com for free, but you have reached the maximum number of pages an unregistered user can view. To register for an account, click here or login below...
